Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy

References

• Braden GL, Mulhern JG, O'Shea MH, et al. Changing incidence of glomerular diseases in adults. Am J Kidney Dis. 2000;35(5):878–883.
   PubMed Web of Science ®Google Scholar
• Haas M, Meehan SM, Karrison TG, et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976–1979 and 1995–1997. Am J Kidney Dis. 1997;30(5):621–631.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. CJASN. 2006;1(3):483–487.
   PubMed Web of Science ®Google Scholar
• Honkanen E, Tornroth T, Gronhagen-Riska C. Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transplant. 1992;7(1):35–41.
   PubMedGoogle Scholar
• Zhu P, Zhou FD, Wang SX, et al. Increasing frequency of idiopathic membranous nephropathy in primary glomerular disease: a 10-year renal biopsy study from a single Chinese nephrology centre. Nephrology. 2015;20(8):560–566.
   PubMed Web of Science ®Google Scholar
• Quarrie M, Emily P. Anti-phospholipase A2 receptor antibodies in primary membranous nephropathy-10 key points. Nephrol Dial Transplant. 2018;33(2):212–213.
   PubMed Web of Science ®Google Scholar
• Beck LH, Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.
   PubMed Web of Science ®Google Scholar
• Cossey LN, Walker PD, Chris PL. Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy. Pediatr Nephrol. 2013;28(12):2307–2311.
   PubMed Web of Science ®Google Scholar
• Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep. 2015;5(1):8803–8812.
   PubMedGoogle Scholar
• Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. JASN. 2015;26(2):302–313.
   Web of Science ®Google Scholar
• Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase A2 receptormediating autoantibody binding in idiopathic membranous nephropathy. JASN. 2015;26(2):291–301.
   Web of Science ®Google Scholar
• Tomas NM, Beck LH, Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277–2287.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Beck LH, Jr, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. JASN. 2017;28(2):520–531.
   Web of Science ®Google Scholar
• Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-1 domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. CJASN. 2017;12(10):1642–1651.
   PubMed Web of Science ®Google Scholar
• Salant DJ. Unmet challenges in membranous nephropathy. Curr Opin Nephrol Hypertens. 2019;28(1):70–76.
   PubMed Web of Science ®Google Scholar
• Chen C, Hsu C, Fang H. Leflunomide in idiopathic membranous nephropathy: a new immunosuppressive with promising treatment potential. Nephrology. 2014;19(1):1–2.
   PubMed Web of Science ®Google Scholar
• Shang S, Li Q, Chen X. Efficacy of leflunomide combined with methylprednisolone in the treatment of idiopathic membranous nephropathy. J Chin PLA Med Coll. 2018;39(1):1–4.
   Google Scholar
• Yang S, Xie L, Xue W, et al. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. Nephrology. 2013;18(9):615–622.
   PubMed Web of Science ®Google Scholar
• Kanigicherla DAK, Hamilton P, Czapla K, et al. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in new-incident and relapsing primary membranous nephropathy. Nephrology (Carlton). 2018;23(1):60–68.
   PubMed Web of Science ®Google Scholar
• Mathrani V, Alejmi A, Griffin S, et al. Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy. Clin Kidney J. 2017;10(4):450–454.
   PubMed Web of Science ®Google Scholar
• Yuan J, Fang W, Zhang W, et al. Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre’s retrospective study. Nephrology (Carlton). 2011;16(4):440–445.
   PubMed Web of Science ®Google Scholar
• Chu X, Xu X, He X, at al. The significance of serum phospholipase A2 receptor antibody in remission of idiopathic membranous nephropathy. Chin J Nephrol. 2018;34(10):752–758.
   Google Scholar
• Kim YG, Choi YW, Kim SY, et al. Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy. Am J Nephrol. 2015;42(3):250–257.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. JASN. 2014;25(6):1357–1366.
   Web of Science ®Google Scholar
• Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Translational Med. 2009;1(5):5–5.
   Web of Science ®Google Scholar
• Wu X, Liu L, Guo Y, et al. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults. Int J Nephrol Renovasc Dis. 2018;20(11):241–247.
   Google Scholar
• Fadieieva A, Prystupa L, Pogorelova O, et al. Role of SLC2A9 and ABCG2 gene polymorphisms in origin of hyperuricemia and gout. Georgian Med News. 2016;252(252):79–83.
   Google Scholar
• Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):735–743.
   Web of Science ®Google Scholar
• Hoxha E, Harendza S, Pinnschmidt HO, et al. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy. Nephrol Dial Transplant. 2015;30(11):1862–1869.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton). 2016;21(2):139–146.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang M, Wang F, et al. The calcineurin regulatory subunit polymorphism and the treatment efficacy of tacrolimus for idiopathic membranous nephropathy. Int Immunopharmacol. 2018;65(1):422–428.
   PubMedGoogle Scholar
• He L, Peng Y, Liu H, et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. JN. 2013;26 (3):564–571.
   Google Scholar
• Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010;339(3):233–238.
   PubMed Web of Science ®Google Scholar
• Van den Brand J, Ruggenenti P, Chianca A, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. JASN. 2017;28(9):2729–2737.
   Web of Science ®Google Scholar
• Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. JASN. 2015;26(10):2545–2558.
   Web of Science ®Google Scholar
• Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. JASN. 2017;28(1):348–358.
   Web of Science ®Google Scholar
• Van de Logt AE, Dahan K, Rousseau A, et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018; 93(4):1016–1017.
   PubMed Web of Science ®Google Scholar
• Eriguchi M, Oka H, Mizobuchi T, et al. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant. 2009;24(10):3082–3088.
   PubMed Web of Science ®Google Scholar
• Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016;78(4):661–671.
   PubMed Web of Science ®Google Scholar
• Liu Y, Qu X, Chen W, et al. Efficacy of leflunomide combined with prednisone in the treatment of refractory nephrotic syndrome. Renal Failure. 2016;38(10):1616–1621.
   PubMed Web of Science ®Google Scholar
• Liang Q, Li H, Xie X, et al. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Renal Failure. 2017;39(1):512–518.
   PubMed Web of Science ®Google Scholar
• Bech AP, Hofstra JM, Brenchley PE, et al. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. CJASN. 2014;9(8):1386–1392.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases?. Autoimmun Rev. 2018;17(10):1022–1027.
   PubMed Web of Science ®Google Scholar
• Qiao G, Yang L, Li Z, et al. A77 1726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells. Clin Immunol. 2015;157(2):166–174.
   PubMed Web of Science ®Google Scholar
• Wijesinghe H, Galappatthy P, de Silva R, et al. Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. BMC Musculoskelet Disord. 2017;18(1):310–320.
   PubMedGoogle Scholar
• An Y, Zhou Y, Bi L, et al. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. Clin Rheumatol. 2019;38(4):1047–1054.
   PubMed Web of Science ®Google Scholar
• Wang E, Jan AS, Doan VP, et al. Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. J Oncol Pharm Pract. 2019;25(7):1731–1737.
   PubMed Web of Science ®Google Scholar
• Li G, Liu T, Bao P. Eficacy Comparison of Leflunomide and Cyclophosphamine treatment on Idiopathic Membranous Nephropathy. Chin J Integrated Traditional Western Med Nephropathy. 2011;12(10):872–874.
   Google Scholar
• He J, Huang J, Wu J, et al. Therapeutic effect of leflunomide combined with prednisone acetate on idiopathic membranous nephropathy. J Chin Pract Diag Therapy. 2011;25(12):1218–1219.
   Google Scholar
• Yan H, Wang W, Cheng Y. Study on effect of leflunomide combined with prednisone in treating idiopathic membranous nephropathy. Chin J Prim Med Pharm. 2014;21(20):3117–3120.
   Google Scholar
• Zhang C, Chu M. Leflunomide: a promising drug with good antitumor potential. Biochem Biophys Res Commun. 2018;496(2):726–730.
   PubMed Web of Science ®Google Scholar